AstraZeneca says Ultomiris shows 3 years relapse-free in NMOSD
(Alliance News) - AstraZeneca PLC on Friday said new long-term clinical trial data reinforce Ultomiris as a transformative treatment for neuromyelitis optica spectrum disorder, or NMOSD, a rare autoimmune disease that can cause blindness and paralysis. Read More